Lung Cancer
Conference Coverage
Adding radiation to immunotherapy may extend PFS in progressive lung cancer
After a median follow-up of 15.2 months, the disease control rate was 57% with the addition of SBRT for patients with metastatic NSCLC who...
From the Journals
Many institutions exceed recommended radiation doses during lung cancer screening
Allowing any radiologist, rather than a lead radiologist, to establish CT protocols is associated with high likelihood of exceeding ACR dose...
Opinion
Long-term survival in stage IV NSCLC
Dr. Alan P. Lyss dissects the clinical significance of two recent studies that examine the long-term survival of patients with stage IV non–small...
Conference Coverage
IMpower131: Improvement in OS for stage IV NSCLC+high-PD-L1 expression
BARCELONA – Patients in the IMpower131 trial with high PD-L1 expression experienced a clinically meaningful improvement in OS with atezolizumab +...
From the Journals
Prior antibiotic use lowers checkpoint inhibitor response and survival
Patients who take antibiotics in the 30 days prior to starting checkpoint inhibitor therapy for cancer have significantly lower overall survival...
Conference Coverage
Tissue TMB disappoints as treatment response biomarker in NSCLC
BARCELONA – Tissue TMB was not significantly associated with treatment efficacy in patients with metastatic nonsquamous NSCLC in the phase 3...
From the Journals
Metformin-TKI combo improves PFS in EGFR-mutated lung cancer
Combination metformin and epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) therapy improved progression-free survival in...
Conference Coverage
LDCT plus miRNA bolsters prevention efforts
BARCELONA – Adding miRNA testing to LDCT lung cancer screening improves prevention efforts with no detrimental effects in lung cancer detection or...
Conference Coverage
MYSTIC trial analysis IDs mutations prognostic of mNSCLC outcomes
An exploratory analysis of MYSTIC trial specimens shows that mutations in the tumor suppressor KEAP1, STK11, and ARID1a genes in mNSCLC genes have...
Conference Coverage
IASLC survey: Ongoing and intensified molecular testing education needed globally
The top five barriers to the use of molecular testing included cost, quality, access, awareness, and time.
Conference Coverage
New IASLC declaration targets tobacco use among cancer patients
BARCELONA – The IASLC has released a new declaration encouraging physicians to screen all cancer patients for tobacco use and to provide tobacco...